Home » Newsletters » BioWorld

BioWorld

Nov. 16, 2009

View Archived Issues

Maxygen Buying Back Stock; Analysts Say No Trend Here

Maxygen Inc. on Friday became the latest member of a very small biotech cadre that is returning cash to shareholders. (BioWorld Today) Read More

Fate Raises $30M in Series B to Advance Stem Cell Product

Study Links Oxidative Damage to BAK, and to Hearing Loss

BioWorld Today Introduces New 'Bench Press' Section

Lawmaker Quizzing Military on Antidepressants, Suicides

Further Troubles at Allston Plant Send Genzyme Shares Sliding

Other News To Note

Clinic Roundup

Appointments And Advancements

Bench Press

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...